Zobrazeno 1 - 10
of 102
pro vyhledávání: ''
Autor:
Jacob J. Rozich, Angelina Collins, Parambir S. Dulai, Jiyu Luo, William J. Sandborn, Brigid S. Boland, Siddharth Singh, Lysianne Pham
Publikováno v:
Inflamm Bowel Dis
Background The incidence and prevalence of inflammatory bowel diseases (IBD) in older adults are rising. There is a limited comparative assessment of risk of disease- and treatment-related complications in older patients (older than 60 years) with ad
Autor:
Hyuk Yoon, Sushrut Jangi, Brian G. Feagan, Brigid S. Boland, William J. Sandborn, Parambir S. Dulai, Siddharth Singh, Vipul Jairath
Publikováno v:
Inflamm Bowel Dis
Background Although achieving histologic remission in ulcerative colitis is established, the incremental benefit of achieving histologic remission in patients with Crohn disease (CD) treated to a target of endoscopic remission is unclear. We evaluate
Autor:
Badr Al-Bawardy, Elizabeth Ruggiero, Edward V. Loftus, Christina Dimopoulos, William A. Faubion, Laurens Janssens, Deborah D. Proctor, David H. Bruining, Kenneth W. Hung, Sunanda V. Kane, Nicholas M. McDonald, Guilherme Piovezani Ramos, Laura E. Raffals
Publikováno v:
Inflammatory Bowel Diseases. 27:1270-1276
Background There are limited data on how vedolizumab (VDZ) impacts extraintestinal manifestations (EIMs) in inflammatory bowel disease (IBD). The aim of this study was to determine the clinical outcomes of EIMs after initiation of VDZ for patients wi
Publikováno v:
Inflammatory Bowel Diseases
Background Clinical indices to characterize the severity of inflammatory bowel disease (IBD) are widely used in clinical trials and real-world practice. However, there are few validated instruments for assessing IBD severity in administrative claims-
Autor:
Sandy H. Fang, Joseph K. Canner, Azah Althumari, Brindusa Truta, Jonathan E. Efron, Bashar Safar, Ira L. Leeds
Publikováno v:
Inflammatory Bowel Diseases. 26:1110-1117
Objectives Early discontinuation of infliximab (IFX) in pregnant women with inflammatory bowel disease (IBD) decreases the intrauterine fetal exposure to the drug but may increase the risk of disease flaring leading to poor pregnancy outcomes. In thi
Autor:
Jonathan R. Ashton, Caroline Duley, Lawrence S. Gaines, Robin Dalal, Ailish Garrett, Dawn B. Beaulieu, Nisha B Shah, Francesca Raffa, Sara N. Horst, Kim Annis, Jennifer Haydek, Julianne H. Wagnon, Elizabeth A. Scoville, Autumn D Zuckerman, Rochelle Wong, David A. Schwartz, James C. Slaughter
Publikováno v:
Inflamm Bowel Dis
Background In inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), nonadherence to biologic therapy increases risk of disease flare. The aim of this study was to identify risk factors for nonadherence. Metho
Autor:
Sarah Lopatin, Benjamin L. Cohen, Ryan C. Ungaro, Bruce E. Sands, Jean-Frederic Colombel, Daniel Castaneda, Robert Hirten
Publikováno v:
Inflamm Bowel Dis
Background Crohn’s disease recurrence after ileocolic resection is common and graded with the Rutgeerts score. There is controversy whether anastomotic ulcers represent disease recurrence and should be included in the grading system. The aim of thi
Autor:
Cilénia Baldaia, Paula Moura dos Santos, Sónia Bernardo, Ana Rita Gonçalves, Carolina Simões, Samuel Raimundo Fernandes, Ana Valente, Rui Tato Marinho, Luís Araújo Correia
Publikováno v:
Inflammatory Bowel Diseases. 26:263-270
BACKGROUND Increasing evidence supports the use of reactive therapeutic drug monitoring (TDM) in Crohn's disease (CD) and ulcerative colitis (UC) following secondary loss of response. It is still unknown if proactive TDM can improve clinical outcomes
Autor:
David J. Bartlett, Ahmad Alsughayer, Amy L. Lightner, Fabian Grass, Kellie L. Mathis, Joel G. Fletcher, David H. Bruining, M. Petersen
Publikováno v:
Inflammatory Bowel Diseases. 25:1845-1853
Background The decision to either escalate medical therapy or proceed to ileocecal resection (ICR) in patients with terminal ileal Crohn disease (CD) remains largely subjective. We sought to develop a risk score for predicting ICR at 1 year from comp
Autor:
Yun Qiu, Yao He, Ting Feng, Jin-Shen He, Shomron Ben-Horin, Baili Chen, Zhirong Zeng, Shenghong Zhang, Minhu Chen, Bella Ungar, Sinan Lin, Ren Mao
Publikováno v:
Inflammatory Bowel Diseases. 25:1813-1821
Background Infliximab levels have been reported to be associated with mucosal healing (MH) in Crohn’s disease (CD). However, whether the association differs between postinduction (week 14) and maintenance (week 30) has seldom been investigated. We